AI digital marketing operator SocialMED will upgrade its digital marketing services to meet the needs of the deep development of digital marketing for pharmaceutical companies with the fresh proceeds.
SocialMED (Chinese: 清赟科技) announced the completion of the Series C round of financing worth tens of millions of USD recently. The round was led by Bayland Capital (Chinese: 康君资本), with the participation from the existing investor Long Hill Capital (Chinese: 长岭资本). Life Venture (Chinese: 生命资本) served as the financial advisor for this round.
The round will be used to accelerate the application upgrade and function innovation of the company's self-developed digital marketing platform and to improve the layout of the omnichannel marketing network in the grassroots market. The company will also use this funding to empower the development and transition of digital marketing of pharmaceutical companies.
Founded in 2017, SocialMED is an AI digital marketing provider focusing on the pharmaceutical industry. The company's integrated multi-channel digital marketing solutions deliver high-value, highly relevant medical knowledge accurately with profound industry insights from medical institutions and doctors at multiple levels, combined with the support of AI and deep machine learning. SocialMED started establishing the omnichannel digital marketing network in the county market in 2021. The network covers more than 700 counties in 20 provinces now.
The company's competitors include Yuemia (Chinese: 悦米科技), Zilue Information (Chinese: 资略信息) and Naxions (Chinese: 诺信创联).